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Objectives. To study the outcome of patients with ruptured AAA treated by EVAR using the Talentw AUI stentgraft
system.
Design. A multicenter prospective consecutive patient cohort of 100 patients.
Materials. Consecutive patients with ruptured AAA will be screened for treatment by EVAR. All patients screened,
including those excluded from EVAR, will be clustered and called the study group. The study group will be compared with a
historical group of patients with ruptured AAA derived from literature. The New ERA study started February 2003.
Outcome. Main outcome events are applicability rate and operative mortality rate of the study group.
Conclusion. The study rationale and design are reported here.
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Background of the Study
Abdominal aortic aneurysms (AAA) larger than
5.5 cm have a significant risk of rupture, which
dramatically increases with aneurysms with diameter
over 6.5 cm.1,2 Open surgical repair has typically been
associated with an inhospital mortality rate of
approximately 50% (40 – 70%).3 – 5 Only a slight
improvement in the outcome of ruptured (r) AAA
over time was documented in a recent meta-analysis
(3.5% reduction per decade), and the mortality rate as
achieved in 2000 was estimated at 41%.6 A number of
non-randomised studies suggest that for elective AAA
treatment, endovascular aneurysm repair (EVAR) is
associated with a lower (major) morbidity and stress
response than open surgery.7 – 11 The reduction in
major morbidity may give an improvement in out-
come in patients with ruptured aneurysms given the
far higher mortality in rAAA treated with conven-
tional open surgery.
Previous Publications
Emergency (e) EVAR has been assessed in a limited
number of studies.12 – 17 The mean number of patients
treated by eEVAR for a documented ruptured infra-
renal AAA in these reports was 15 with a range of 4–
21 patients. The mean first month mortality rate in
these series was 17% (range 0–45%). However, it was
disconcerting that only two reports indicated that their
series consisted of consecutively enrolled patients,
rendering the outcomes in the other reports strongly
influenced by selective patient recruitment. Patients
selected for eEVAR likely constitute a lower risk
category, as they would need to be stable for
preoperative imaging and have a suitable anatomical
configuration. Thus the good outcomes in these
studies may simply reflect selection bias.
An additional point of concern was the applicability
rate of eEVAR. In studies that did indicate the
proportion of patients with rAAA that received
eEVAR, this rate varied from 27% to 78%.12 – 14,16,17
While the concept of eEVAR will lose much of its
appeal if it can only be applied to the minority of
patients, one must take into account that the criteria of
eligibility were based on those customarily used in
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elective EVAR. However, it may be appropriate to
consider less stringent anatomical criteria in patients
with rAAA, in particular larger infrarenal neck
diameters. Elective repair of AAAs with large neck
diameters has not been associated with an increased
incidence of proximal endoleak.18 Rigid application of
industry imposed criteria and overly cautious appli-
cation, well justified in elective AAA-repair, seems
counterproductive in emergency treatment of rAAA.
Rationale for Study Design
The New ERA study was conceived to allow an
assessment of the feasibility of eEVAR. All patients
presenting with rAAA within a study period and not
only the subset treatable by EVAR will be included. In
addition, this consecutive series with preferential
eEVAR (the study group) will be compared with a
comparable historical cohort that was treated by
conventional open surgery.
A randomised comparative trial (RCT) to assess the
value of eEVAR for rAAA would be ideal. However, in
our opinion a RCT conducted at the present time,
would be biased against the endo-technique. These
biases include: the influence of a learning curve, an
insufficiently developed infrastructure for rapid pre-
operative imaging and a quick execution of an
emergency endovascular procedure in hospitals, tra-
ditionally familiarity with urgent open aneurysm
repair and insufficient number of endovascular
specialists available for on-call rostas. A non-random-
ised cohort study with preferential eEVAR allows the
opportunity for a comparison of the primary outcome
events with the outcome of up to date meta-analysis
and to resolve any organisational issues within the
study centers.
Organisation of the Study
The New ERA study is a prospective, multicenter,
feasibility European and Canadian study that is
sponsored by Medtronicw and supported by the
Medtronicw Bakken Research Centre. The objective is
to evaluate applicability, clinical performance, safety
and effectiveness of stentgraft placement in rAAA
using the Talentw AUI stentgraft system. Vascular
surgeons and interventional radiologists with con-
siderable experience in the diagnosis and treatment of
rAAA have been included as investigators in this
study (list of participating investigators is reported in
Appendix A). Patient data and procedural details are
recorded in structured Case Report Forms (CRFs),
periodically monitored by the organising company.
Adverse events are reported to and evaluated by an
Adverse Event Advisory Committee. Some of the
members in this committee represent the Medtronicw
company (AEAC, members of AEAC are reported in
Appendix B). Study conduct is supervised by the
Steering Committee (Appendix C) consisting of
representatives of Medtronicw and clinical
professionals.
An adverse event (AE) is any undesirable clinical
occurrence in a patient whether or not related to the
device. Any change in nature, severity, or degree of a
pre-existing condition is also recorded as an AE. An
SAE is recorded if the patient’s hospitalization is
prolonged or the patient requires re-admission,
another intervention or dies. Twelve centers will
participate in this study. The evaluation of the study
objectives requires 100 patients, each with a follow-up
of 3-months. The study has started in February 2003.
A consecutive series of patients treated for ruptured
infrarenal abdominal aortic aneurysms (rAAA) is
included in the study, in each of the participating
institutions. The preferential treatment will be EVAR,
open surgery is only selected as treatment when
anatomic criteria preclude effective exclusion of the
aneurysm, or if the patient is in profound hypovolemic
shock that does not allow pre-operative CT scanning
or the use of intravascular ultrasound to evaluate
EVAR feasibility. Included in the study are patients
treated by stentgraft technique or, in the case of
adverse anatomy for endoluminal stentgrafting, by
open surgery. Patients who are suitable for EVAR will
be treated with the aorto-uni-iliac (AUI) Talentw
stentgraft system (Fig. 1).
The Talentw stentgraft configuration consists of a 2-
piece AUI with interchangeable proximal and distal
components, for ‘off-the-shelf’ customisation with
variable diameters and lengths. The 2-piece AUI
configuration potentially reduces the complexity of
the procedure compared to a bifurcated design,
contributing to quicker aneurysm exclusion.
Purpose and Objectives
The purposes of the New ERA study are:
1. to assess the proportion of patients, presenting with
rAAA in whom EVAR is applicable,
2. to determine operative mortality and morbidity in
a cohort of patients treated with EVAR, when
possible.
Study endpoints include: operative mortality,
defined as death within the first 30 days or during
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the same hospitalisation and major morbidity (i.e.
serious adverse events). Secondary endpoints include:
death from all causes and aneurysm-related death,
both within three months after the procedure.
Patient Selection, Inclusion and Exclusion Criteria
for the Study
During the study period each participating center will
enrol a series of consecutive patients with a rAAA that
meet the inclusion criteria. Rupture of the aneurysm is
defined as haemorrhage outside the aortic wall,
documented by preoperative CT-examination, preo-
perative ultrasound, or in case of a laparotomy by
direct observation. In the case that there is still doubt
after treatment whether the AAA was ruptured,
rupture is to be confirmed by postoperative CT-scan
or by autopsy. The patient, or his/her relatives are
informed about the study and asked permission to
participate by a written informed consent. The criteria
for enrolment in the study, and after enrolment,
eligibility for EVAR, are summarised in Table 1.
Triage of Patients that Meet the Inclusion Criteria
Patients in stable haemodynamic condition, or with
mild to moderate haemodynamic instability (systolic
blood pressure .60 mmHg and no severe cardiac
arrhythmia) undergo CT-examination. Arrangements
for CT-examination without any delay and short
transportation time between the emergency ward,
the CT-department and the operative department are
prerequisites for participating institutions (Fig. 2—
flow sheet).
Severely unstable patients in profound hypovole-
mic shock that does not allow CT-scanning (i.e. systolic
blood pressure ,60 mmHg and/or repeated require-
ment for cardiac massage due to severe cardiac
arrhythmia) are taken to the operating room and
clinically evaluated and if possible undergo fluoro-
scopic assessment to establish whether an EVAR or
open surgical procedure can be performed.
The anatomic criteria determining treatment by
open surgery include an infrarenal aortic neck length
smaller than 10 mm and/or a diameter larger than
32 mm. In addition, an angulation of the infrarenal
neck larger than 858 excludes the patient from EVAR.
Bilateral iliac artery occlusions or stenosis (,6 mm
diameter), not amenable to balloon angioplasty,
represent exclusion criteria for EVAR. These patients
are included in the study cohort, but are recorded to be
ineligible for EVAR on anatomic grounds.
Guidelines for Emergency AAA Stentgraft
Procedures
The resuscitation of a patient with a ruptured AAA
requires a multidisciplinary approach. It involves
emergency, radiology, anaesthesiology, operating
theatre and surgical staff. We prefer to maintain
systolic blood pressure between 60 and 100 mmHg
Fig. 1. The components of the Talentw aorto-uni-iliac
stentgraft system used for emergency EVAR.
Table 1. Inclusion and exclusion criteria for the New ERA study
Inclusion criteria
Age .50 years
Patients with documented rupture of the
infrarenal aorta (preoperative CT, preoperative ultrasound,
laparotomy, postoperative CT-scan, autopsy)
Written informed consent by patient or
legal representative
Exclusion criteria
No documentation of true rupture
Rupture because of endoleak of a
stentgraft placed before the study has
started
Severe dementia
Active infection
Malignancy with life expectancy less than
one year
No consent to participate in the
study
Deliberate decision of the patient (or
representatives) to be treated by open
surgery
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and avoid general anaesthesia. Emergency CT imaging
should be available at all times. The responsible
surgeon confirms the diagnosis of rAAA (extravasa-
tion of blood), verifies the length and diameter of the
neck and then decides whether EVAR or open surgery
is the appropriate treatment.
Severe hypotension (less than 60 mmHg) can be
treated by blood and crystalloid transfusion. Pain and
anxiety can be treated by intravenous Fentanyl
administering. If the blood pressure is .100 mmHg
systolic, Nitroproside or Ketansin is administered
intravenously to lower the blood pressure. As soon
as the decision is taken whether EVAR is possible the
patient is quickly transported to the operating room
for surgery.
The Talentw aorto-uni-iliac stentgraft is favoured
over a bi-iliac stent graft because it is presumed to be
the quickest way to exclude an aneurysm from the
systemic circulation.19 An additional advantage of
using an aorto-uni-iliac (AUI) device of one single
company is that no subgroups need to be formed in the
analysis and therefore the study does not lose power.
Emergency EVAR starts with local anaesthesia of
the groin at the selected access side. After introduction
of an angiography catheter, the renal arteries are
marked on the fluoroscopy-display and the proximal
part of the standard aorto-uni-iliac set is deployed.
Then quickly the distal component of the stentgraft to
the selected iliac artery is deployed. Sealing within the
common iliac arteries is preferred over extending the
device into the external iliac artery. Colon ischemia
from hypogastric artery inflow occlusion is a real risk.
The contralateral common femoral artery is now
exposed under local anaesthesia, and this artery is
used for introduction of the ‘Occluder device’ (Fig. 1)
into the common iliac artery (if this artery is markedly
aneurysmal the contralateral external iliac artery and
hypogastric arteries are ligated via a small lower
quadrant incision with retroperitoneal approach). The
operation is finalised by performing a cross-over
femorofemoral bypass under general anaesthesia. A
completion angiogram is performed to check whether
there are gross endoleaks.
Type I and III endoleaks have to be treated as soon
as possible. Therefore they will be treated direct after
the ‘completion angiogram’ in the same session,
modifications are to the discretion of the participating
physicians. Type II and IV endoleaks are accepted.
Type II endoleaks are treated if there is growth of the
aneurysm at follow-up. If Type IV endoleaks do not
resolve in 30 days there should be concern that there is
another type of endoleak present. All patients are
postoperatively treated in the Intensive Care Unit.
Although the procedure described above is feasible,
modifications are to the discretion of the participating
physicians. Expedient preoperative CT-examination is
Fig. 2. Flow sheet for patients with ruptured abdominal aneurysms entering the hospital.
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strongly recommended, and it should be performed in
the large majority of patients. However, in the case of
extreme haemodynamic instability (systolic blood
pressure ,60 mmHg or severe cardiac arrhythmia)
surgeons may decide to transport a patient immedi-
ately to the operating room. Depending on the
circumstances one may choose to perform an angio-
gram using a C-arm fluoroscopy to determine whether
EVAR is a reasonable option or to proceed with open
surgery without imaging.
Follow-up and Adverse Events
Clinical and imaging follow-up will be performed at 3
months after the intervention. Adverse events are
documented, CT imaging results and secondary
procedures are recorded.
Study Population and Statistical Analysis
Applicability
The applicability of the endovascular technique would
be considered unsatisfactory if it were below 50%.
Thus, the null hypothesis: applicability ¼ 50% will be
tested against the one-sided alternative of a higher
applicability rate. The expected applicability rate is at
least 70%. With alpha set to 0.1 and a sample size of 100
patients the power would be 93%.
Mortality
The intention is to demonstrate that the mortality rate
of patients with rAAA, treated by preferential EVAR,
is lower than 50%. The null hypothesis of a first-month
mortality of 50% or greater will be tested against the
one-sided alternative of a lower mortality, using the
exact binomial test. If a mortality rate of 25% is assumed
in the group of patients treated by endovascular
technique, and of 50% in the open surgery group, the
overall mortality adds up to 32.5%, if the applicability of
the endovascular technique is 70%. Under these
assumptions and an alpha of 0.1 a sample size of 100
results in a power of 87% to reject the null hypothesis.
Secondary analysis
Preferential treatment will be EVAR, and open surgery
will be performed only if patients do not meet the
anatomical criteria for EVAR, or if the patient is in
profound hypovolemic shock that does not allow CT-
scanning or the use of IVUS during the operative
procedure. A comparative, secondary, descriptive
analysis between patients of the study group (patients
undergoing endoluminal treatment and patients
undergoing open surgery) and a historical patient
group, with morbidity and mortality rates derived
from literature, will be performed.
All case report forms, patient informed consents, data
on adverse events will be reported by the investigator and
monitored by Medtronic. An Adverse Event Advisory
Committee (AEAC) will review all severe or serious
adverse events, device- or procedure-related, including
death. Device-related and SAEs will be reported to all
investigators. Each clinical participating site has obtained
approval of the local ethical committee for the protocol.
Data handling and analysis will be performed by the
Department of Medtronic Clinical Research in
co-operation with the chief clinical investigator.
Current Status
Recruitment began February 2003, and by the end of
January 2004 a total of 59 patients have been included,
representing 59% of the target. Final results of ERA
should be available in 2005.
Conclusion
In this new era of endoluminal treatment, stentgrafting
for ruptured infra-renal aneurysms has been reported
in several non-consecutive, non-randomised trials
with fair to good results. However, these results may
be due to selection bias. The New ERA study is
designed to diminish selection bias and optimise the
applicability of EVAR. In the study, an international
multicenter cohort of patients with rAAA will be
treated preferentially by eEVAR, and the outcome of
this group compared with that of patients with rAAA
treated by conventional open surgery as reported in
large series in the literature. If the results are again as
promising as the first reports of treatment of rAAA
with stentgrafting, this study may pave the way to a
randomised comparative trial for patients with rAAA.
About the ERA Study
The study is sponsored and supported by Medtronicw
Bakken Research Center.
The Adverse Event Advisory Committee and the
Steering Committee consists of members who are
affiliated to Medtronicw and members who are not
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affiliated to Medtronicw. Statistical analysis will be
performed by Medtronic Biostatistics and Data Manage-
ment Department, Santa Rosa (CA).
Appendix Participants of the ERA-Study
J. Buth (principal investigator), P. Cuypers and
N. Peppelenbosch, Eindhoven, J. Teijink, H. Odink
and R. Welten, C.X. Heerlen, R.H. Geelkerken, A.B.
Huisman, D.G. Gerrits, E.D.P. Volker, R. van Det and
P. De Smit, Enschede, The Netherlands, J. De Letter,
Brugge, F. E.G. Vermassen, and I. van Herzeele, Gent,
Belgium, P. Cao, F. Verzini, and S. Mosca, Perugia,
Italy, M.M. Thompson, R. Morgan, and A. Belli,
London, United Kingdom, C. Soong, C. Boyd, and
W. Loan, Belfast, Northern Ireland, M. Lepa¨ntalo, P.
Keto, W. Roth, and Pekka Aho, Helsinki, Finland,
G. Walterbusch, N. Keck, and J. Beyer, Dortmund,
Germany, G. DeRose, T.L. Forbes, and S.W. Kribs,
London, Ontario, O. K. Steinmetz, K. MacKenzie, D.
Obrand, and B. Montreuil, Montreal, Quebec, Canada.
Appendix Adverse Event Advisory Committee
B. Barbieri, and S. Zannetti, Medtronic Bakken
Research Center, Maastricht, J. v d Berg, Nieuwegein,
The Netherlands, P. Cao, Perugia, Italy.
Appendix Steering Committee Members
B. Barbieri and S. Zannetti, Medtronic Bakken Research
Center, Maastricht, J.J. Jackimovicz, J. Buth, P. Cuypers
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